The use of anti-TNF agents and the occurrence of severe sepsis and re-activation of tuberculosis has been reported. Their use should be avoided if serious infections (e.g. septic arthritis, acute abcess, systemic fungal infactions) are present or are likely to recur.
The manufacturer of infliximab recommends that patients are screened for tuberculosis prior to therapy, and advised to seek help if they develop symptoms such as persistent cough, weight loss or fever that may suggest tuberculosis. Due to the long half-life of infliximab the patient should be "monitored" closely for infection for at least 6 months after stopping the drug.
Infliximab should be avoided in pregnancy and effective contraceptive measures should be taken. Women should not breast feed for at least 6 months after stopping treatment.
Annotations allow you to add information to this page that would be handy to have on hand during a consultation. E.g. a website or number. This information will always show when you visit this page.